Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens by Denys, Gerald A. et al.
Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution
Activity against Clinical Target and Antimicrobial-Resistant Pathogens
Gerald A. Denys,a Chris M. Pillar,b Daniel F. Sahm,b Peter O’Hanley,c Jackson T. Stephens, Jr.c
Indiana University School of Medicine, Indianapolis, Indiana, USAa; Eurofins Medinet, Chantilly, Virginia, USAb; Exoxemis, Inc., Little Rock, Arkansas, USAc
This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target
pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solutionmaintained potent
activity against all bacterial species studied for each year tested, withMICs ranging from<0.008 to 0.25g porcine myeloperox-
idase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical iso-
lates and organisms with challenging resistance phenotypes.
E-101 solution is a novel antimicrobial agent with broad-spec-trum activity against both Gram-negative and Gram-positive
pathogens, including drug-resistant strains. E-101 solution is an
enzyme-based topical formulation composed of glucose oxidase
(GO) and porcine myeloperoxidase (pMPO) in an aqueous vehi-
cle. Topical application of E-101 solution with glucose activates in
situ GO production of hydrogen peroxide (H2O2) that drives
pMPO-dependent oxidation of chloride to hypochlorous acid
(HOCl). The reaction of H2O2 with HOCl yields singlet molecular
oxygen (1O2). The microbicidal action of E-101 solution involves
the binding of pMPO to the surfaces of target microorganisms,
where HOCl and 1O2 effect direct oxidative damage to the micro-
organisms (1–6).
E-101 solution represents the first-in-class topical myeloper-
oxidase-based microbicidal formulation applied directly to surgi-
cal wounds to prevent surgical-site infections (SSI). It is currently
being tested in a pivotal phase 3 clinical trial (i.e., the Triple-IN
Study) for the prevention of SSI after colorectal surgery. Infections
caused by antimicrobial-resistant pathogens have become com-
mon and are increasingly difficult to treat (7). As part of the clin-
ical development of E-101 solution, it is important to monitor any
changes in activity that may indicate the emergence of resistance.
This study reports the in vitro susceptibility results of E-101 solu-
tion against target SSI pathogens isolated from relevant clinical
specimens from patients seeking medical care in the United States
over a 5-year period (2008 to 2012). In addition, we evaluated the
activity of E-101 solution against highly resistant ESKAPE (En-
terococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Entero-
bacter species) pathogens and other current problem pathogens
with emerging resistance (8, 9).
A total of 760 nonduplicate, nonconsecutive clinical isolates of
Staphylococcus aureus, coagulase-negative staphylococci, entero-
cocci, Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae,
Proteus mirabilis, and Enterobacter cloacae), and Pseudomonas
aeruginosa collected from 75 sites across the 9 U.S. census regions
were evaluated (Table 1). Among the isolates tested were those
with multidrug-resistant (MDR) phenotypes. A total of 103 non-
duplicate clinical isolates of ESKAPE pathogens were preselected
based on resistance phenotype and genetic characterization from
both the Eurofins Medinet and NARSA repositories (Table 2).
Evaluated ESKAPE pathogens included the following: S. aureus,
including 10 hospital-acquired methicillin-resistant S. aureus
(HA-MRSA) isolates (1 USA600 and 9 USA100 clones), 10 com-
munity-acquired MRSA isolates (CA-MRSA) (10 USA300
clones), 7 daptomycin-nonsusceptible S. aureus isolates, 9 lin-
ezolid-resistant S. aureus isolates, and 8 vancomycin-nonsuscep-
tible S. aureus isolates (3 vancomycin-resistant S. aureus [VRSA]
and 5 vancomycin-intermediate S. aureus [VISA] isolates); En-
terococcus spp., including 9 vancomycin-resistant (5 E. faecalis and
4 E. faecium) isolates; Enterobacteriaceae, including 10 extended-
spectrum--lactamase (ESBL)-producing isolates (5 E. coli and 5
K. pneumoniae isolates), 10 carbapenemase-producing K. pneu-
moniae (KPC) isolates, and 10 derepressed AmpC cephalospori-
nase-producing isolates (5 Citrobacter spp. and 5 Enterobacter
spp.); and 20 MDR isolates, including 10 Acinetobacter baumannii
and 10 P. aeruginosa isolates. ESBLs were phenotypically defined
on prior testing as a2-fold reduction in ceftazidime/cefotaxime
MIC when combined with clavulanic acid (10). KPC-2 and KPC-3
carbapenemases were confirmed by real-time PCR (11). Dere-
pressed AmpC cephalosporinase was phenotypically defined on
prior testing as resistant to cefoxitin, ceftazidime, and cefotaxime,
not inhibited by clavulanic acid, and susceptible to carbapenems
(12). MDR bacteria were classified based on prior testing and on
recommended guidelines (13). MDR bacteria were defined as
nonsusceptible to 1 antimicrobial agents in 3 antimicrobial
classes.
Antimicrobial susceptibility testing was performed using a
modified broth microdilution method based on CLSI M7 guide-
lines as previously described (14, 15). Modifications to CLSI M7
were made to accommodate the rapid in vitro activity of E-101
solution. In the modified method, the first E-101 enzyme solu-
tion containing pMPO was diluted in double-strength cation-
adjusted Mueller-Hinton broth (CAMHB), resulting in doubling
dilutions throughout the microdilution panel. Next, a standard-
ized bacterial suspension, prepared in double-strength glucose
substrate solution, was added to each well and mixed with enzyme
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dilutions. Each antimicrobial agent and enzyme solution was di-
luted in CAMHB and dispensed in microdilution panels. Isolates
were prepared by suspending several colonies from an overnight
culture on Trypticase soy agar with 5% sheep blood in sterile sa-
line, and the density was adjusted to a turbidity equivalent to that
of a 0.5 McFarland standard (108 CFU/ml). Standardized bac-
terial suspensions were further diluted in double-strength glucose
substrate solution and mixed with serial drug dilutions to achieve
a final concentration of 5 105 CFU/ml. E-101 solution begins to
generate reactive oxygen species immediately postinoculation,
The microdilution panels were incubated in ambient air at 35°C
for 18 to 24 h. MICs were determined by observing the lowest
concentration of antimicrobial agent that inhibited growth of the
organisms and was expressed as g pMPO/ml in E-101 solution.
Quality control ranges determined for E-101 solution for S. aureus
ATCC 29213 and E. coli ATCC 25922 were 0.01 to 0.03 g
pMPO/ml and 0.15 to 0.5g pMPO/ml, respectively (14). Isolates
were concurrently tested against relevant comparators in accor-
dance with CLSI M7 (13). Quality control organisms included S.
aureus ATCC 29213, E. faecalis ATCC 29212, E. coli ATCC 25922,
and P. aeruginosa ATCC 27853.
Table 1 summarizes the MICs of E-101 solution for each year
tested. Based on MIC50s and MIC90s, E-101 solution maintained a
high level of activity ( one doubling dilution). From 2008 to
2012, we observed no increase in the MIC distribution of isolates
tested. The E-101 solution MIC ranges for the staphylococci
maintained the highest level of potency (0.008 to 0.03 g
pMPO/ml). The distribution of MICs was very similar for all phe-















Range 50% 90% Range 50% 90% Range 50% 90%
S. aureus 50 0.008–0.03 0.015 0.015 50 0.008–0.015 0.015 0.015 50 0.008–0.015 0.008 0.008
CoNSb 30 0.008–0.03 0.015 0.015 30 0.008–0.03 0.008 0.015 30 0.008-0.03 0.015 0.03
E. faecalis 15 0.06–0.25 0.25 0.25 15 0.12–0.25 0.25 0.25 15 0.06-0.5 0.25 0.25
E. faecium 15 0.03–0.12 0.06 0.12 15 0.06–0.25 0.06 0.12 15 0.03–0.25 0.06 0.12
E. coli 30 0.015–0.12 0.12 0.12 30 0.12–0.25 0.25 0.25 30 0.06–0.25 0.12 0.12
K. pneumoniae 30 0.06–0.25 0.25 0.25 30 0.06–0.25 0.12 0.25 30 0.03–0.25 0.12 0.12
Enterobacter spp. 30 0.03–0.12 0.12 0.12 30 0.06–0.25 0.12 0.12 30 0.03–0.12 0.06 0.06
P. mirabilis 30 0.008–0.06 0.03 0.03 30 0.015–0.06 0.03 0.06 30 0.015–0.06 0.03 0.03
P. aeruginosa 30 0.008–0.12 0.03 0.06 30 0.015–0.25 0.06 0.12 30 0.015–0.12 0.03 0.06
a MICs are the concentrations of pMPO (g/ml) in E-101 solution.
b CNS, coagulase-negative staphylococci.





Range Mode 50% 90%
S. aureus Overall 44 0.008–0.06 0.008 0.008 0.015
HA-MRSAb 10 0.008–0.015 0.008 0.008 0.008
CA-MRSAb 10 0.008–0.015 0.015 0.015 0.015
DAP NS 7 0.008–0.06 0.008 NA NA
LZD R 9 0.008–0.015 0.008 NA NA
VAN NS 8 0.008–0.008 0.008 0.008 0.008
Enterococcus spp. VRE 9 0.03–0.12 0.12 NA NA
Enterobacteriaceae Overall 30 0.015–0.25 0.12 0.12 0.12
ESBLc 10 0.06–0.25 0.12 0.12 0.12
KPCd 10 0.12–0.12 0.12 0.12 0.12
Derepressed AmpCe 10 0.015–0.06 0.06 0.06 0.06
A. baumannii MDRf 10 0.03–0.03 0.03 0.03 0.03
P. aeruginosa MDRf 10 0.015–0.06 0.03 0.03 0.06
a HA-MRSA, hospital-acquired methicillin-resistant S. aureus; CA-MRSA, community-acquired MRSA; DAP NS, daptomycin nonsusceptible; LZD R, linezolid resistant; VAN NS,
vancomycin nonsusceptible; VRE, vancomycin-resistant enterococci; ESBL, extended-spectrum -lactamase; KPC, Klebsiella pneumoniae carbapenemase; AmpC cephalosporinase;
MDR, multidrug resistant.
b HA- and CA-MRSA designations are based on the USA type reported in the NARSA (Network on Antimicrobial Resistance in Staphylococcus aureus) repository.
c Phenotypically positive in prior testing, with a2-fold reduction in ceftazidime/cefotaxime MIC when combined with clavulanic acid (10).
d Positive for KPC-2/KPC-3 by PCR (11).
e Phenotypically positive based on prior testing (cefoxitin resistant, ceftazidime resistant, cefotaxime resistant, not inhibited by clavulanic acid, carbapenem susceptible) (12).
f MDR was based on prior testing and defined as resistance to 3 or more different antimicrobial classes (13).
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notypes tested. The E-101 solution MIC ranges for E. faecalis and
E. faecium were very similar during each test period. E-101 solu-
tion was consistently more active against E. faecium (MIC50, 0.06
g pMPO/ml, and MIC90, 0.12 g pMPO/ml) than E. faecalis
(MIC50 and MIC90, 0.25 g pMPO/ml). The E-101 solution
MIC50s and MIC90s obtained for each species among the Entero-
bacteriaceae also reflected a high level of potency of E-101 solution
that has been maintained against most recent organisms. Multi-
drug resistance among Enterobacteriaceae evaluated had no im-
pact on E-101 solution activity. The E-101 solution MIC50s and
MIC90s for P. aeruginosa also showed a high level of potency of
E-101 solution that has been maintained against most recent or-
ganisms, including MDR strains.
The activity of E-101 solution against resistant ESKAPE patho-
gens was equivalent to that observed for E-101 solution during
recent surveillance testing, where isolates with these phenotypes
were infrequent or not encountered (Table 2). E-101 solution
maintained potent MICs (0.015 g pMPO/ml or less excluding
one daptomycin-nonsusceptible isolate) overall against S. aureus
isolates, including those resistant to current agents against Gram-
positive organisms. E-101 solution was active against prevalent
HA-MRSA and CA-MRSA clones. Among the enterococci, E-101
solution maintained potency against vancomycin-resistant en-
terococci, with MICs in the 0.03- to 0.12-g pMPO/ml range.
E-101 solution MICs were 2-fold lower against vancomycin-resis-
tant E. faecium (0.03 to 0.06 g pMPO/ml) than vancomycin-
resistant E. faecalis (0.06 to 0.12 g pMPO/ml). Against various
species and types of -lactamase-producing Enterobacteriaceae,
E-101 solution maintained potent MICs, including the recently
emerged KPC-producing K. pneumoniae. Against A. baumannii,
including all evaluated MDRA. baumannii isolates, E-101solution
had MICs of 0.03 g pMPO/ml. E-101 solution was also highly
active against MDR P. aeruginosa, with an MIC50 of 0.03 g
pMPO/ml and an MIC90 of 0.06 g pMPO/ml.
Prevention of SSIs remains an important medical need in high-
risk surgical patient populations, such as colorectal surgery pa-
tients, transplant patients, and patients receiving implant devices.
Improvement in infection control practices and topical antiseptics
that are tissue safe and broadly microbicidal for any potential
pathogen for wound management are needed. Topical antiseptics
currently on the market are associated with local tissue injury and
impairment of wound healing when applied directly to clean or
infected wounds. E-101 solution is intended for direct application
to wounds and wound margins without associated tissue injury.
Previous studies using the partial full-thickness pig wound model
have shown that topical application of E-101 solution to surgical
wounds does not impair subsequent wound healing (16). Further-
more, E-101 solution has demonstrated in vivo efficacy in whole-
animal models of surgical infection prevention (17, 18).
Across in vitro studies to date, E-101 solution has demon-
strated greater overall in vitro activity than gentamicin and mupi-
rocin against both Gram-negative and Gram-positive pathogens
(14). Data from this surveillance study confirm earlier studies and
demonstrate that E-101 solution had high in vitro potency and a
broad spectrum of activity against many circulating isolates in the
United States during 2008 and 2012. In addition, E-101 solution
was potent in vitro against ESKAPE pathogens, which constitute
clinically important pathogens with problematic mechanisms of
resistance to commonly utilized agents. The emergence and
spread of resistance combined with the increasing prevalence of
multidrug resistance among ESKAPE pathogens have left rela-
tively few effective therapeutic options for the treatment of drug-
resistant infections. This attribute highlights the important utility
of E-101 solution as a prophylactic agent for the prevention of
SSIs, where resistant organisms are likely to be encountered, as
well as other superficial infections caused by resistant organisms.
In summary, the MIC results of this longitudinal 5-year sur-
veillance study indicate that E-101 continues to maintain a high
level of activity against all target organism groups. No significant
longitudinal changes in MICs further support the efficacy of E-101
solution, especially for preventing SSIs with organisms likely to be
encountered clinically at present, including those with problem-
atic resistance to other currently utilized agents. Continued mon-
itoring of E-101 solution activity is warranted during clinical test-
ing so that any changes in the level of activity can be detected in a
timely matter.
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